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Abstract
Introduction Restoration of blood flow following ischemic
stroke can be achieved by means of thrombolysis or
mechanical recanalization. However, for some patients,
reperfusion may exacerbate the injury initially caused by
ischemia, producing a so-called “cerebral reperfusion
injury”. Multiple pathological processes are involved in
this injury, including leukocyte infiltration, platelet and
complement activation, postischemic hyperperfusion, and
breakdown of the blood–brain barrier.
Methods/results and conclusions Magnetic resonance im-
aging (MRI) can provide extensive information on this
process of injury, and may have a role in the future in
stratifying patients’ risk for reperfusion injury following
recanalization. Moreover, different MRI modalities can be
used to investigate the various mechanisms of reperfusion
injury. Antileukocyte antibodies, brain cooling and condi-
tioned blood reperfusion are potential therapeutic strategies
for lessening or eliminating reperfusion injury, and inter-
ventionalists may play a role in the future in using some of
these therapies in combination with thrombolysis or
embolectomy. The present review summarizes the mecha-
nisms of reperfusion injury and focuses on the way each of
those mechanisms can be evaluated by different MRI
modalities. The potential therapeutic strategies are also
discussed.
Keywords Magneticresonanceimaging.Cerebral
ischemia.Reperfusioninjury.Hypothermia.
Conditionedbloodreperfusion
Introduction
In the treatment of acute stroke, restoration of the blood
supply can reduce more extensive brain tissue injured by
salvaging a reversibly damage penumbra of tissue [1]. This
mechanism provides a rationale for clinical trials which
have demonstrated that reperfusion after thrombolysis
improves clinical outcome in selected patients with acute
stroke [2].
Reperfusion, however, carries certain risks. Some
patients experience disastrous outcomes in the form of fatal
edema or intracranial hemorrhage following thrombolysis
[3]. In some animal stroke models [4, 5], reperfusion after a
long ischemic period can cause a larger infarct than that
associated with permanent vessel occlusion. Thus, while
reperfusion may reduce infarct size and improve clinical
outcome in some patients, in others it may exacerbate the
brain injury and produce a so-called “cerebral reperfusion
injury” [4, 6, 7]. Cerebral reperfusion injury can be defined
as a deterioration of ischemic but salvageable brain tissue
after reperfusion.
Thrombolysis [2] and embolectomy [8, 9] usually result
in reperfusion of the infarcted brain tissue and therefore
carry the risk of causing reperfusion injury. Thus reperfu-
sion injury deserves the attention of those interested in the
diagnosis and treatment of acute stroke. Strategies to reduce
or minimize cerebral reperfusion injury require the under-
standing of the pathophysiology of cerebral reperfusion
injury, and the way the reperfusion injury is visualized by
magnetic resonance imaging (MRI). Therapeutic options
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Cerebral reperfusion injury: mechanisms
and correlation with MRI
Leukocyte infiltration and secondary ischemia as depicted
with DW MRI
Leukocytes play an important role in the development of
cerebral reperfusion injury. During reperfusion, activated
leukocytes interact with endothelial cells and plug capillar-
ies, disrupt the blood-brain barrier (BBB) through the
release of neutrophil-derived oxidants and proteolytic
enzymes, extravasate from capillaries and infiltrate brain
tissue, and release cytokines which mediate inflammation.
These processes produce an inflammatory cascade, result-
ing in the deterioration of the salvageable penumbra [7].
Evidence of the deleterious effects caused by leukocytes
is provided by animal studies. For example, Zhang et al.
[10], using a rat model of 2 hours transient focal cerebral
ischemia induced by advancing a nylon monofilament to
occlude the middle cerebral artery (MCA), showed that
neutrophils accumulate at the site of neuronal injury 6 hours
after restoration of cerebral circulation. The neutrophil
accumulation occurred earlier and to a greater extent in
reperfusion tissue than in tissue permanently deprived of
blood supply [10]. Furthermore, this study showed that the
infarct volume increased dramatically between 6 and
24 hours following the start of reperfusion, and that the
period of maximal infarct expansion correlated closely with
the time course of neutrophil infiltration.
The contribution of leukocytes to cerebral reperfusion
injury is also supported by the beneficial effects of
neutrophil depletion. Bednar et al. [11] investigated the
effect of administering antineutrophil antiserum treatment
on brain infarct size in a rabbit model of transient ischemia.
The regional cerebral blood flow (CBF) of neutropenic
rabbits recovered from less than 5 ml/100 g per minute to
20–30 ml/100 g per minute following reperfusion, while in
the non-neutropenic rabbits it remained at less than 10 ml/
100 g per minute. Correspondingly, the infarct size was
significantly smaller in the neutropenic animals. Similar
results have been reported in rats treated with antineutrophil
monoclonal antibodies [12].
The evidence from animal experiments points to the role
of neutrophils in restricting CBF and increasing infarct size
during reperfusion. High-quality evidence of reperfusion-
induced secondary ischemic injury has been obtained using
diffusion-weighted imaging (DWI) in animals. Further-
more, the evolution of reperfusion injury can be depicted by
observing dynamic changes with DWI (Fig. 1)[ 13].
Olah et al. [13] investigated the dynamics of the apparent
diffusion coefficient (ADC) in a rat model with 1 hour of
MCA occlusion (MCAO) followed by 10 hours of
reperfusion. They found that the ADC was decreased at
the end of ischemia, then significantly improved during the
first 2 hours of reperfusion (Fig. 2), but decreased again at
later time points with a secondary increase of hemisphere
lesion volume. The ADC change most likely reflects a
secondary ischemic injury. Although a potential role for
apoptosis cannot be excluded, the observed secondary
deterioration of ADC did not support apoptosis as a major
mechanism, because the ADC decline indicated cell
swelling and not loss of cell volume, which is a
fundamental and universal characteristic of programmed
cell death [14]. Similarly, Neumann-Haefelin et al., also
using a rat MCAO model, showed that DWI abnormalities
reversed transiently during the early reperfusion period but
recurred after several hours of restored blood flow [15].
Likewise, Li et al., using a rat model with 10–30 minutes of
temporary MCAO, observed that the DWI hyperintensity
seen during the initial ischemic insult reverted to normal
approximately 60–90 minutes after the start of reperfusion,
with secondary hyperintensities emerging 12 hours after
reperfusion [16]. The secondary increase of DWI signal
intensity observed in these studies is likely a marker of
cerebral reperfusion injury [15].
Several interesting characteristics of the ADC changes
during reperfusion have been reported in animal studies.
First, the time of onset of the secondary reduction of ADC
varies amongst different animal studies, ranging from 2–
72 hours after reperfusion [12, 16–18]. The reason is
probably due to the different durations of the initial
ischemic insult and differences in the animal model used.
Second, the secondary deterioration of ADC can be
predicted by early changes of T2 during reperfusion. Olah
et al. [13], in their rat model study, observed that an
increase in T2 value early in the ischemic period predicts a
secondary deterioration in ADC after reperfusion. This
suggests the possibility of using T2 value clinically to
predict the extent of reperfusion injury likely to follow
recanalization, and may be useful in assessing patients’
likelihood of benefiting from thrombolysis.
Hemorrhagic transformation (HT) follows hyperperfu-
sion and disruption of the BBB (see below), but some of
the imaging studies are reviewed in this section because
there is a close relationship between the ADC changes and
the subsequent HT after cerebral ischemia. In a rabbit
model of thromboembolic stroke, Adami et al. [19]
compared the percentage of pixels with very low ADC at
various time points after the start of ischemia with the
subsequent occurrence of HT (as determined on histopath-
ological sections). The authors found that, at each time
point, regions populated by pixels with an ADC value
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−6 mm
2/s were likely to
undergo HT, and that the percentage of pixels below this
threshold correlated with the severity of HT. This result has
also been confirmed in several human studies. In a group of
acute stroke patients treated with intravenous recombinant
tissue plasminogen activator (rtPA) within 3 hours from
symptom onset, Selim et al. [20] demonstrated that the
absolute number of voxels with ADC values ≤550×10
−6
mm
2/s was much higher in patients with HT than in those
without. The authors suggested that, although patients with
both small and large DWI lesions have the tendency to
develop HT, the volume of ischemic tissue with ADC
≤550×10
−6 mm
2/s may best predict the risk of intracere-
bral HT after thrombolysis.
ADC values have also been reported to correlate with
recanalization and clinical outcome in ischemic stroke
patients undergoing local intra-arterial thrombolysis. Taleb
et al. [21] identified two patient groups on angiographic
findings: one group with more than 50% recanalization and
the other with less than 50%. Relative ADC values were
found to be higher in the first group of patients. Moreover,
all patients in the recanalization group had a Barthel index
of 80 or more, whereas eight of ten patients in the
nonrecanalization group had a Barthel index of 50 or less.
Fig. 1 D W Ii m a g e so far a tm o d e lw i t h1h o u ro fM C Ao c c l u s i o n
(MCAO) followed by 10 hours of reperfusion. These images show
the evolution of ADC at different times: before ischemia (control), at
the end of MCAO, and at different time points of reperfusion. Note
the transient recovery of ADC during the early phase of reperfusion,
followed by secondary deterioration (reproduced with permission
from Olah et al. [13])
Fig. 2 Temporal evolution of mean relative ADC in the end-ischemic
lesion volume in a rat model with 1 hour of MCA occlusion (MCAO)
followed by 10 hours of reperfusion. Although a significant
improvement in ADC attends reperfusion, there is a secondary
deterioration likely as a consequence of the reperfusion-related injury
(reproduced with permission from Olah et al. [13])
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The mechanisms of leukocyte infiltration are characterized
by leukocyte activation, leukocyte–endothelial interaction
resulting in accumulation in the vascular bed, followed by
leukocyte extravasation into the interstitial space. Each of
these mechanisms is briefly reviewed.
The accumulation of leukocytes, along with red blood
cells and platelets during reperfusion, may plug capillaries,
preventing the restoration of blood flow and resulting in a
“no-reflow” phenomenon and secondary cerebral ischemia
[22–27]. Del Zoppo et al. [27] used a microscopic imaging
system in a baboon model of transient ischemia. There was
significant capillary obstruction caused by leukocytes
reperfusing the microvascular bed within 60 minutes after
the restoration of cerebral circulation. The “no-reflow”
phenomenon explains well the better recovery of regional
CBF in neutropenic rabbits [11].
The molecular mechanisms by which leukocytes infil-
trate the parenchyma during reperfusion have been eluci-
dated. This multistage process can be conceptually divided
as follows: (1) leukocytes “rolling” on the endothelium, (2)
firm adherence of leukocytes to the endothelium, and (3)
transmigration into the tissue [1, 28–31]. Superoxide free
radicals produced during ischemia and reperfusion cause
the upregulation of endothelial P-selectin. Once leuko-
cytes reach the ischemic territory the endothelial P-selectin
interacts with its leukocyte counter-receptor P-selectin
glycoprotein 1 [31]. This initial interaction facilitates the
low affinity “rolling” of leukocytes on the endothelium.
Firm adherence is developed with subsequent interaction
of the leukocyte β2 integrins CD11a/CD18 and CD11b/
CD18 with endothelial intercellular adhesion molecule 1
(ICAM-1).
The transmigration of leukocytes results from the
expression of platelet-endothelial cell adhesion molecule-1
(PECAM-1) along the endothelial cell junction. Once the
leukocytes infiltrate the parenchyma, they then release
various chemical mediators including neutrophil elastase,
reactive oxygen species (ROS), leukotrienes, and prosta-
glandins, resulting in increased microvascular permeability,
edema, thrombosis and parenchymal cell death [1, 27, 32].
This process compounds the initial injury that occurred in
these tissues during the hypoxic insult.
Platelet-mediated reperfusion injury
Platelets play a synergistic role with leukocytes in reperfu-
sion injury. Several studies suggest that platelets are
activated after cerebral ischemia and reperfusion [33–35].
Following activation, platelets may adhere to both leuko-
cytes and cerebral microvascular endothelial cells, contrib-
uting to the “no-reflow” phenomenon and furthering tissue
injury. Additionally, activated platelets release a variety of
biochemical mediators of tissue injury.
Several studies have confirmed that platelet activation
occurs in patients with stroke. Zeller et al. [36] used flow
cytometric detection of platelet adhesion molecules as a
marker of platelet activation, and reported a substantially
greater activation in acute stroke patients than in normal
controls. Similarly, van Kooten et al. [37], using urinary
excretion of 11-dehydro-thromboxane-B2 as a marker of
platelet activation, demonstrated a 347% increase in the
marker excretion in ischemic stroke patients compared with
matched controls.
Chong et al. [38] investigated changes in platelet–
leukocyte adhesion using a rat model of transient MCA
ischemia. The authors reported that platelet–neutrophil
adhesion was significantly increased from 16.6% in the
control group to 39% in the reperfusion group (P<0.01).
Platelets in the stroke group expressed high levels of P-
selectin. It was hypothesized that enhancement of platelet–
leukocyte adhesion may be mediated by increased P-
selectin expression on the platelet membrane.
Studies on the role of platelets in coronary reperfusion of
the heart suggest that, in addition to causing mechanical
obstruction, platelets can cause temporary vasospasm by
releasing serotonin, thromboxane A2, and free radicals.
This can cause diminished reperfusion of the ischemic
territory [33]. Further, activated platelets can release
mediators that may cause chemotaxis and migration of
leukocytes, thus exacerbating the inflammatory cascade
[33]. These mechanisms may also prove to be important in
cerebral reperfusion injury after ischemic stroke.
Complement-mediated reperfusion injury
Experimental studies have shown that complement activa-
tion is an important component of reperfusion injury in
several organ systems. Complement may be activated
during reperfusion through the antibody-dependent classi-
cal pathway, the alternative pathway, or the MBL/MASP
(mannan-binding lectin/mannan-binding lectin-associated
serine proteases) pathway [39, 40]. Complement activation
results in the formation of several inflammatory mediators,
including anaphylatoxins C3a, C5a, and the distal comple-
ment component C5b-9 (membrane attack complex, MAC)
[39]. C5a and the MAC are the best-characterized effectors
of tissue damage within the complement system [41, 42].
C5a may stimulate leukocyte infiltration into the ischemia
and reperfusion injury-affected tissue by its strong chemo-
taxis action. C5a may also further amplify the inflammatory
response by inducing the release of several proinflamma-
tory cytokines, including IL-1, IL-6, monocyte chemo-
attractant protein 1 (MCP-1) and tumor necrosis factor α
(TNF-α). MAC can cause cellular membrane injury directly
96 Neuroradiology (2007) 49:93–102and can increase cell membrane permeability. Furthermore,
MAC plays an essential role in mediating the recruitment of
leukocytes to the reperfused tissue via local induction of IL-
8. Several agents that inhibit all or part of the complement
components such as cobra venom factor (CVF) [43], C5a
monoclonal antibodies [44], and Cl esterase inhibitor [45],
have been shown to significantly attenuate the degree of
reperfusion injury in animal models, providing further
evidence that complement plays an important role in
reperfusion injury.
Postischemic hyperperfusion and PWI
Postischemic hyperperfusion is recognized as a frequent
occurrence in stroke. Several animal studies suggest that the
restoration of cerebral circulation consistently results in a
hyperperfusion phase. Hyperperfusion may contribute to
the development of reperfusion injury by causing brain
edema or hemorrhage. Further, following postischemic
hyperperfusion, a phase of secondary hypoperfusion can
occur, which results in harmful effects on the reperfused
tissue [1, 46, 47].
Heiss et al. [46] observed the effects of hyperperfusion
in cats using a model of temporary MCA occlusion of
varying durations (30, 60, and 120 minutes). In the 30-
minute group, only a transient reactive hyperperfusion
(compared with preocclusion values) was found. All
animals in this group survived during the observation
period, and no cerebral injury was found on histological
study. In the 60- and 120-minute groups, the degree of
hyperperfusion was significant, reaching up to 300% of
preocclusion values. Most importantly, a clear difference
was found between surviving and dying cats. In dying cats,
postischemic hyperperfusion was long and severe, large
infarcts developed and intracranial pressure increased
fatally. In surviving cats postischemic hyperperfusion was
transient and less severe, infarcts were smaller and
intracranial pressure was significantly lower. A report of a
similar study design suggested that the degree of hyper-
perfusion correlates significantly with occurrence of intra-
cerebral petechial hemorrhages in the damaged cortex [47].
Perfusion-weighted imaging (PWI) provides quantitative
and qualitative maps of CBF, cerebral blood volume
(CBV), and mean transit time (MTT), allowing identifica-
tion of regions of relative hypo- and hyperperfusion [48].
Kidwell et al. [48] used PW MRI to characterize hyper-
perfusion in 12 patients following intra-arterial thrombol-
ysis. Hyperperfusion was visualized in 5 of 12 patients. On
day 7, 79% of voxels with hyperperfusion demonstrated
infarction, whereas only 36% not showing hyperperfusion
demonstrated infarction. Despite the voxel-by-voxel asso-
ciation of hyperperfusion with infarction, there were no
significant differences in the degree of clinical improve-
ment in patients with regions of hyperperfusion versus
those without. It has been reported that reduction in volume
of hypoperfused brain on PWI is a marker of response to
treatment and improved function in ischemic stroke patients
[49]. Larger future studies are necessary to assess the extent
to which both hyperperfusion and hypoperfusion may result
in unfavorable clinical outcome.
Breakdown of the BBB and contrast-enhanced MRI
Breakdown of the BBB during cerebral reperfusion may
lead to the development of vasogenic edema, HT and
infarction, all contributing to cerebral reperfusion injury.
This hypothesis has been supported by several clinical and
animal studies [5, 50–52].
Sage and Duffy [50] investigated the increase in BBB
permeability after transient global cerebral ischemia in a rat
model. Permeability of the BBB was increased at
15 minutes after reperfusion of the brain, and cerebral
edema occurred 15–30 minutes after reperfusion. Another
study reported a disruption of the BBB after 3 hours of
reperfusion, following a 3-hour temporary occlusion [5]. In
contrast, the BBB remained intact after 6 hours of occlusion
in a permanent occlusion group. Moreover, the temporary
occlusion group had increased ipsilateral hemispheric water
content, suggesting that cerebral edema had occurred. In
addition to these reports, numerous histological studies with
various tracers have established that reperfusion may
exacerbate vasogenic edema due to BBB disruption [6,
53, 54].
T2-weighted imaging is useful for detecting vasogenic
edema. Neumann-Haefelin et al. [15] used several MRI
techniques to monitor the dynamics of secondary ischemic
damage, BBB disturbances, and development of vasogenic
edema during the reperfusion phase after focal cerebral
ischemia in rats. After 2.5 hours of ischemia, signal
intensity on both DWI and T2-weighted images increased
rapidly in the previously ischemic region due to BBB
disruption (enhancement on postcontrast T1-weighted
images) and edema formation. More importantly, early
BBB damage after reperfusion appeared to be predictive of
relatively pronounced increases in T2 lesion size due to
vasogenic edema at subacute time points (1 to 2 days).
Using a novel MRI marker that can image BBB
disruption, Latour et al. [55] studied a total of 144 acute
stroke patients, to test the association between reperfusion,
HT and clinical outcome. Nearly two-thirds (63%) of the
patients had evidence of reperfusion within 1 week. BBB
disruption was more common in patients who reperfused
(45%) than in patients who did not reperfuse (18%). Both
HT and BBB disruption were more common in patients
undergoing intra-arterial rtPA therapy (31% and 55%), than
those not treated (14% and 25%). In the reperfused group,
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poor clinical outcome (63%) than those without disruption
(25%). Moreover, early BBB disruption was an indepen-
dent predictor of HT. This was a key study because it
associated early BBB disruption with HT and poor clinical
outcome in humans.
Contrast-enhanced T1-weighted MRI can detect disrup-
tion of the BBB during reperfusion. Under normal
physiological conditions, contrast agent does not cross the
intact BBB. Mechanisms that cause BBB disturbances,
such as reperfusion injury, result in leakage of the contrast
agent into the brain. In a recent study, rats were subjected
either to permanent MCA occlusion, reperfusion after
1 hour (early reperfusion), or reperfusion after 3 hours of
MCAO (late reperfusion) [56]. This protocol allowed
monitoring the evolution of BBB disruption during perma-
nent or temporary MCAO. Contrast agent extravasation
was found in all animals with permanent MCAO and late-
reperfusion animals, but in only 40% of early-reperfusion
animals. Postischemic hyperperfusion was demonstrated in
late-reperfusion animals, but not in early-reperfusion
animals. Thus, using contrast-enhanced MRI, the disruption
of the BBB was correlated with the hemodynamic and
biophysical consequences of reperfusion.
Fenstermacher et al. [57] employed the Patlak plot
processing of gadolinium-shifted T1 relaxation-time images
to obtain quantitative estimations of BBB opening in rats.
Following 2.5 hours of reperfusion, the “blood-tissue
distribution” of gadolinium-T1-shifted protons was serially
imaged every 3–4 minutes for 20–30 minutes. After that,
the value of blood-to-brain transfer constants (K1) for
gadolinium was calculated from the serial changes of the
relaxation time via Patlak plots [58] of MRI-T1 datasets.
The K1 for gadolinium in ischemia and reperfusion areas
was around 200 times larger than that of normal areas,
indicating a huge impairment of BBB function during
ischemia and reperfusion. This approach may be utilized to
monitor the time-course of BBB function in transient
cerebral ischemia.
The disruption of the BBB has also been observed in
ischemic stroke patients undergoing rtPA therapy. A
retrospective study of 213 patients used the postcontrast
enhancement of the cerebrospinal fluid (CSF) in FLAIR
images (termed hyperintense acute reperfusion marker,
HARM) to characterize early BBB disruption [59]. BBB
disruption was more common in patients with reperfusion
(45%) than in patients without reperfusion (18%, P=
0.006). In multiple logistic regression, reperfusion was the
strongest independent predictor of early BBB disruption
(OR 4.09, 95% CI 1.28 to 13.1, P=0.018). HARM was
associated with HT and worse clinical outcome. This is a
key study for two reasons: first, the association between
reperfusion, BBB disruption and HT was established in
humans, and second, it may be possible to reduce the
complications of rtPA by targeting adjunctive therapies
against BBB disruption. In another recent study, three of
the six patients receiving rtPA showed early parenchymal
enhancement, and all three of them went on to develop HT,
whereas none of the patients without early parenchymal
enhancement developed hemorrhage [60]. The results
suggest that early parenchymal enhancement may be
significantly correlated with subsequent symptomatic HT
and may be helpful in identifying patients at risk after
thrombolytic therapy.
Potential therapeutic strategies
With the progress made in the understanding of the
mechanisms in cerebral ischemia and reperfusion injury,
an increasing number of strategies have been developed for
limiting or preventing further brain damage during reperfu-
sion [61–64]. Many of these strategies interfere with
leukocyte infiltration. Two previously described animal
studies indicated that leukocyte depletion with either
antineutrophil antiserum treatment or with antineutrophil
monoclonal antibody leads to better recovery of regional
CBF and significantly reduces infarct size after cerebral
reperfusion [11, 12]. Similarly, anti-ICAM-1 monoclonal
antibodies reduce neutrophil infiltration and lesion size
after reperfusion in rats, while they are ineffective in
permanent ischemia [65], suggesting that ICAM-1 may be
an attractive therapeutic target that specifically addresses
the problem of reperfusion injury.
However, the translation of these promising antileuko-
cyte strategies into effective therapies in humans has been
disappointing. A randomized controlled trial (RCT) evalu-
ated the use of enlimomab, a murine ICAM-1 antibody, in
625 ischemic stroke patients [66]. Patients were random-
ized to receive either enlimomab for 5 days or placebo
within 6 hours after stroke onset. At 90 days, the modified
Rankin scale score was worse in patients treated with
enlimomab. Moreover, the hazard of death was 43% higher
on enlimomab than on placebo. There are several possible
explanations for the failure of enlimomab to produce the
desired effects. It is possible that the positive results seen
with anti-ICAM therapy in animal studies do not reflect the
immunological response in human stroke. Alternatively,
ICAM-1 therapy may be effective only after reperfusion
[65], and it is believed that only a minority of patients
experience complete reperfusion after ischemic stroke [67].
Thus, it may have been more appropriate to try enlimomab
in patients who received thrombolytic therapy.
Another RCT randomized 966 ischemic stroke patients
presenting within 6 hours of acute stroke to either placebo
or UK-279,276, a CD11b/CD18 inhibitor. Of these patients,
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prematurely terminated when an interim analysis showed
that the trial would be unable to demonstrate the benefit of
this therapy in terms of improvement in Scandinavian
Stroke Scale score at 90 days.
Some conventional drugs have been shown in animal
experiments to provide effective neuroprotection. For
example, studies in a rat model have demonstrated that
both dextran sulfate and unfractionated heparin can effec-
tively prevent leukocyte infiltration and reduce infarct
volume after reperfusion [69, 70]. Although the actual
mechanism is still unclear, these findings suggest a possible
role for these agents alongside other therapeutic modalities
that cause recanalization (i.e. intravenous/intra-arterial
rtPA, mechanical thrombolectomy) [69, 70]. Trials investi-
gating this approach in humans have yet to be conducted.
Besides these drug therapies, there are two management
strategies, brain cooling and conditioned blood perfusion,
which are reviewed in some detail because they can
modulate several pathways/mechanisms that contribute to
reperfusion injury. Both strategies are promising, and
interventional neuroradiologists may have a role in admin-
istering these therapies in the future.
Brain cooling
Reports on the role of hypothermia in humans are
encouraging. Two large RCTs established conclusively the
neuroprotective effects and safety of systemic hypothermia
after cardiac arrest [71, 72]. A meta-analysis of the results
[73] showed that patients in the hypothermia group were
more likely to be discharged with no or only minimal
neurological damage (risk ratio 1.68; 95% CI 1.29–2.07).
This translated to six as the a number needed to treat in
order to prevent one death or serious neurological deficit.
There are no hypothermia efficacy studies in ischemic
stroke patients. Several animal studies of temporary MCAO
have shown that systemic hypothermia applied up to 3 hours
after reperfusion has started is effective in reducing infarct
volume (by 50–90%) and reducing animal mortality [74,
75]. Moreover, hypothermia exerts its neuroprotective
effects partly by suppressing the BBB opening [76, 77]
and by attenuating neutrophil infiltration in the ischemic
penumbra [78, 79]. Hence, hypothermia exerts at least
some of its neuroprotective effects by modulating mecha-
nisms responsible for reperfusion injury.
In most clinical studies, hypothermia is induced by
surface cooling with the use of cooling blankets, alcohol
applied to exposed skin, or ice bags to groin, axilla and
neck. Although whole-body surface cooling is the simplest
and most cost-effective option for inducing hypothermia
[80], it has two major drawbacks. First, it takes several
hours to reach the target body core temperature. All studies
report a 3- to 7-hour time period for cooling down to 32–
34°C [81–84]. Target temperature should be reached as
soon as possible to prevent reperfusion injury; the 3–7 hour
time period to reach target temperature is too long and the
therapeutic window will be missed for many patients.
Theoretical models predict that intracerebral hypothermia
can be achieved up to 30 times faster than whole-body
hypothermia [85]. The second drawback of whole-body
cooling is the high incidence of complications such as
pneumonia, arrhythmias/bradycardias, hypotension and
coagulopathies [81–83, 86, 87]. Selective brain cooling
may dramatically improve the safety profile of therapeutic
hypothermia. Selective brain cooling can be achieved by
means of an endovascular catheter that infuses the cerebral
vasculature with cold saline. A recent study examined
whether cold saline (20°C) infused intra-arterially into the
ischemic territory of rats that had undergone MCA
occlusion could selectively induce cerebral hypothermia
and reduce brain injury from stroke [88]. Following cold
saline infusion, cerebral temperature fell within 1 min to
33.4°C, while rectal temperature was maintained above 36°C
at all times. A significantly reduced infarct volume was
found in ischemic rats that received a local cooling infusion
compared with control animals (Fig. 3). Further clinical
research is needed to explore the therapeutic potential of
selective brain cooling and the yet-unknown adverse effects,
as well as to establish the extent to which selective brain
cooling specifically modulates reperfusion injury.
Conditioned blood reperfusion
Conditioned blood reperfusion is a therapeutic strategy in
which the ischemic organ is perfused with autologous
Fig. 3 Graph showing percentages of infarct volume in the four
ischemic rat groups (stroke, stroke with local infusion of saline at 20°C
and 37°C, and stroke with systemic infusion at 20°C). A significantly
(P<0.001) reduced infarct volume was found in ischemic rats that
received a local cooling infusion compared with the rats in the other
three groups (reproduced with permission from Ding et al. [88])
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conditioned by filtration is depleted of leukocytes and
platelets, both at levels far greater than 99.99%, and the
complement cascade is modulated in such a way as to
prevent the deposition of MAC onto ischemic tissue [89].
Filtering the reperfused blood in this manner may reduce
further tissue damage after restoration of circulation [89,
90]. Blood can be filtered using the conditioned blood
reperfusion application (CoBRA) filter (Pall B-1328 filter;
Pall Corporation, East Hill, N.Y.) at the onset of reperfusion
[89]. Withdrawn arterial blood can be filtered through the
CoBRA filter and returned back to the cerebral circulation
via an endovascular catheter. A small feasibility and safety
clinical trial of blood filtering during primary percutaneous
transluminal coronary angioplasty for acute myocardial
infarction demonstrated that integration of the CoBRA
filter into an active hemoperfusion system did not delay the
procedure or cause any complications [89]. Furthermore,
conditioned blood reperfusion resulted in an acute im-
provement in ventricular function. Animal models of
hypothermic circulatory arrest have demonstrated improve-
ment of neurological outcomes following conditioned
blood reperfusion [91–93]. In one of these studies, pigs
received blood filtered using the CoBRA filter [92]. Each
pig received a common carotid artery filtered perfusion for
10 minutes. Pigs receiving conditioned perfusion had
significantly better neurological scores than control pigs
(P<0.005). These findings suggest that multifocal inter-
vention aimed at leukocytes, platelets and complement
attenuation can dramatically improve neurological recovery
from ischemic insult. Future studies will establish the
efficacy of this strategy and the incidence of possible
adverse effects, such as coagulapathies and infections.
Further studies are needed to evaluate the role of local
hypothermia and conditioned blood perfusion in reducing
postischemic reperfusion injury. It is possible, yet still
speculative, that in the future interventional neuroradiolo-
gists may use these approaches following recanalization
with thrombolytic agents or mechanical embolectomy to
lessen reperfusion injury.
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